Question-and-Answer Session
Operator
(Operator Instructions). And our first question comes from the line of Alan Carr with Needham. Go ahead.
Alan Carr - Needham & Company
Hi good afternoon everyone.
Uli Hacksell
Hi there.
Alan Carr - Needham & Company
Hi, yeah, sounds like you’re making some progress with the Pimavanserin in PDP and that you’ve that enrollment is, I guess little bit more clear here in terms of time lines. I was wondering if you can give any more detail on when you think you might get the second one started? And has your view changed, as whether or not this one is going to be exactly the same as the first or you are going to – are there going to be any differences between the two trials.
Uli Hacksell
Roger, may be you can give a short-term answer to that question.
Roger Mills
Yeah, thanks Uli. So Alan, I think this will be the strategy was to position the two studies in a staggered manner, but obviously in parallel. So as we’ve been doing lot of work in getting the first study up and running, we’ve been doing the preparatory work for and that's well underway. So we will anticipate starting that study probably soon.
Alan Carr - Needham & Company
In the first half '08 probably, or even by yearend, do you think?
Roger Mills
Actually starting, I won't give the exact time but it will be a lot faster than the end of '08 I can assure you, its.
Alan Carr - Needham & Company
At first half?
Roger Mills
Probably soon.
Alan Carr - Needham & Company
Okay. And I guess that we missed, but didn't ask about partnering for Pimavanserin and can -- I am wondering if you can characterize those discussions to any degree as to whether or not, are you finding any hesitation for patterning this drug because its an agent as apposed to a standalone drug or are there particular financial term that you are looking for?
Uli Hacksell
Yes, so let me try to answer that question. First of all, as we have indicated following the completion of the full analysis of our trial, we initiate this process to explore potential strategic alliances that really can help us to optimize the value of Pimavanserin. What we can say is that we have been very pleased with the positive reaction on the Phase II data from both the medical and pharmaceutical communities. And what I can tell you is that following the full analysis of the data from this trial, we are more excited than ever above the commercial potential for Pimavanserin and we believe that this excitement is also evident in this captions with potential partners.
- To read the full transcript on Seeking Alpha, click here »
